BORDERLINE RESECTABLE PANCREATIC DUCTAL ADENOCARCINOMA
Clinical trials for BORDERLINE RESECTABLE PANCREATIC DUCTAL ADENOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new BORDERLINE RESECTABLE PANCREATIC DUCTAL ADENOCARCINOMA trials appear
Sign up with your email to follow new studies for BORDERLINE RESECTABLE PANCREATIC DUCTAL ADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug targets pancreatic cancer before surgery
Disease control Not yet recruitingThis early-stage trial tests a drug called samuraciclib in 15 people with localized pancreatic cancer that can be surgically removed. Participants will take the drug for about two weeks before their planned surgery. Researchers will check safety and look for changes in tumor cell…
Matched conditions: BORDERLINE RESECTABLE PANCREATIC DUCTAL ADENOCARCINOMA
Phase: PHASE1 • Sponsor: University of Washington • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
Genetic test may guide chemo choice for pancreatic cancer patients
Disease control Not yet recruitingThis phase II trial tests whether a genetic signature can personalize chemotherapy for people with borderline resectable pancreatic cancer. About 110 participants will receive either a standard chemo regimen or one chosen based on their tumor's genetic profile. The goal is to see…
Matched conditions: BORDERLINE RESECTABLE PANCREATIC DUCTAL ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Federation Francophone de Cancerologie Digestive • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
New drug AB801 aims to boost chemo and immunotherapy in tough cancers
Disease control Not yet recruitingThis early-phase trial tests a new drug called AB801, which blocks a protein (AXL) that helps cancers grow and resist treatment. It is given alongside chemotherapy and immunotherapy to people with bile duct or pancreatic cancer that is either borderline resectable, locally advanc…
Matched conditions: BORDERLINE RESECTABLE PANCREATIC DUCTAL ADENOCARCINOMA
Phase: PHASE1 • Sponsor: Jonsson Comprehensive Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC